Navigation Links
BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman
Date:10/20/2009

SAN DIEGO, Oct. 20 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary neural stem cell platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced the appointment of Drs. Edward Scolnick from the Broad Institute of MIT and Harvard and David Holtzman of Washington University School of Medicine to its scientific advisory board. The appointees join BrainCells' advisory boards comprised of world-class scientists of neurogenesis and CNS disease. Existing board members represent The Salk Institute, Columbia University, Stanford University, Cedars-Sinai Medical Center and Massachusetts General Hospital.

"Ed and David are two highly esteemed and accomplished neuroscientists; a great honor for the company and a validation of our research in neurogenesis," said Jim Schoeneck, chief executive officer of BrainCells Inc. "Their backgrounds in research and drug development will be invaluable as we prioritize clinical applications for our assets. In the past five years, we've screened more than 1,000 compounds against 150 novel and known mechanisms, moved neurogenic compounds into Phase 2 clinical trials and identified several preclinical candidates."

Dr. Edward Scolnick is an internationally recognized thought leader in neuroscience research. He currently serves as director of the Psychiatric Disease Program and the Stanley Center for Psychiatric Research at the Broad Institute, focused on identifying risk genes for bipolar disorder and schizophrenia. Prior to joining the Broad Institute, Dr. Scolnick spent more than 20 years with Merck in various positions including president of Merck Research Laboratories. He has also worked at the National Cancer Institute and National Heart Association. Dr. Scolnick is a member of National Academy of Sciences, the American Academy of Arts and Sciences and the Institute of Medicine. He served on the board of Directors at Merck & Co., Inc. from 1997 to 2002 and is a current board member for Millipore Corporation and Alnylam Pharmaceuticals. Dr. Scolnick holds an A.B. from Harvard College and an M.D. from Harvard University Medical School.

Dr. David Holtzman is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center, and a member of the Hope Center for Neurological Disorders at Washington University School of Medicine. His research focuses on understanding basic mechanisms underlying acute and chronic cell dysfunction in the CNS, particularly how mechanisms may relate to Alzheimer's disease and injury to the developing brain. Prior to Washington University, Dr. Holtzman established the Memory and Cognitive Disorders Clinic at UCSF. Over the course of his career Dr. Holtzman has been recognized with the Paul Beeson Physician Faculty Scholar Award in Aging Research, the Potamkin Prize from the American Academy of Neurology for research on Alzheimer's, election to the American Society for Clinical Investigation, recipient of a MERIT award from the NIA, the MetLife award on Alzheimer's disease and election to the Institute of Medicine of the National Academy of Sciences. Dr. Holtzman holds a B.S. and M.D. from Northwestern University.

About BrainCells Inc.

BrainCells Inc. (BCI) is a drug discovery and development company leading the scientific research of neurogenesis by applying its robust and proprietary platform technology to identify novel pathways for new therapeutics to treat various central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of indications. For more information, visit http://www.braincellsinc.com.

    Media Contact:
    Kim Richards
    Porter Novelli Life Sciences
    619-849-5377
    krichards@pnlifesciences.com

SOURCE BrainCells Inc.


'/>"/>
SOURCE BrainCells Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
2. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
3. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
4. Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
7. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
8. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
9. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
10. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
11. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):